CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Moderate Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has received an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $69.00.

A number of analysts have weighed in on CGON shares. The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Royal Bank Of Canada increased their target price on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. HC Wainwright lifted their price target on shares of CG Oncology from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Finally, Piper Sandler upped their price objective on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th.

CG Oncology Stock Performance

CGON opened at $63.84 on Wednesday. CG Oncology has a one year low of $14.80 and a one year high of $69.35. The company has a market cap of $5.39 billion, a P/E ratio of -30.84 and a beta of 1.18. The business’s 50-day simple moving average is $57.33 and its 200-day simple moving average is $46.65.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. As a group, analysts predict that CG Oncology will post -1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 1,964 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $63.50, for a total value of $124,714.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology in the fourth quarter valued at approximately $27,000. Strengthening Families & Communities LLC purchased a new position in shares of CG Oncology during the third quarter worth approximately $40,000. Comerica Bank increased its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after acquiring an additional 515 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of CG Oncology by 15.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after acquiring an additional 433 shares during the period. Finally, Picton Mahoney Asset Management purchased a new stake in CG Oncology in the 4th quarter valued at $118,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.